Streetbeat News

KRRO

Korro Bio, Inc.

https://www.korrobio.com

Industry

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Open

28.27

Mkt cap

231M

Volume

110K

High

28.49

P/E Ratio

-2.61

52-wk high

98.00

Low

23.69

Div yield

N/A

52-wk low

18.50

United Airlines reported better-than-expected earnings, leading to a 9.3% stock increase. Other stocks like Korro Bio, Wave Life Sciences, and Morgan Stanley also saw significant gains due to positive developments.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 2:23 pm

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Korro Bio (NASDAQ:KRRO) and maintained a price target of $95.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:09 pm

Novo Nordisk has entered a $600 million partnership with NanoVation Therapeutics to develop genetic medicines targeting cardiometabolic and rare diseases. The collaboration will utilize NanoVation's lipid nanoparticle technology. Novo Nordisk also announced a collaboration with Korro Bio for RNA editing therapies.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 7:30 pm

U.S. stocks mostly rose with the Nasdaq Composite gaining 0.2%. Energy shares increased by 1.3%, while healthcare shares fell by 1.1%. Notable stock movements included BurgerFi International's 88% rise, Galmed Pharmaceuticals' 422% surge, and Compass Minerals' 24% gain. Tupperware Brands dropped 58% amid bankruptcy concerns.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 6:31 pm

U.S. stocks rose with the Dow Jones, NASDAQ, and S&P 500 all gaining. Notable stock movements included BurgerFi International's 96% surge after securing financing, Galmed Pharmaceuticals' 99% jump after regaining Nasdaq compliance, and Compass Minerals' 28% rise on strong revenue forecasts. Tupperware Brands fell 58% amid bankruptcy concerns, while Netcapital and Korro Bio also saw declines.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 4:16 pm

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Korro Bio (NASDAQ:KRRO) and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 10:57 am

Korro Bio's stock is rising following a collaboration announcement with Novo Nordisk to develop genetic medicines targeting cardiometabolic diseases.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:26 pm

Korro Bio has announced a collaboration with Novo Nordisk to develop two therapeutic candidates using Korro's OPERA platform for RNA editing, targeting cardiometabolic diseases. The deal is valued at up to $530 million, including milestone payments, royalties, and R&D funding.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:12 pm

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) with an Outperform rating, highlighting its proprietary OPERA platform for RNA editing. The analyst also noted the upcoming clinical data release from Wave Life Sciences Ltd (NASDAQ:WVE) and mentioned Beam Therapeutics Inc (NASDAQ:BEAM) as a validating but differentiable competitor.

Portfolio Pulse from Vandana Singh

August 14, 2024 | 6:21 pm

RBC Capital analyst Luca Issi maintains an Outperform rating on Korro Bio (NASDAQ:KRRO) but lowers the price target from $105 to $95.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.